NASDAQ$INDV
Indivior Pharmaceuticals Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Indivior reported Q1 2026 revenue of $317.0M and net income of $89.0M, with diluted EPS of $0.69.
For Q1 2026, Indivior reported revenue of $317.0M and net income of $89.0M. The quarterly 10-Q discusses segment performance, liquidity, and outlook in MD&A.
- Revenue of $317.0M for Q1 2026.
- Net income of $89.0M; diluted EPS $0.69.
- Operating trends and segment mix are detailed in the quarterly report.
- Liquidity, capital allocation, and macro exposure discussed in MD&A.
Headline financials
Revenue & EPS history
Indivior · Revenue · Quarterly
$317M
Forward guidance
The 10-Q discusses Indivior's operating environment, capital priorities, and risks without issuing formal quarterly EPS guidance.
Tailwinds
- Management provides segment and liquidity detail in MD&A.
- Filing supports transparency on year-over-year trends.
Headwinds
- Macro, competitive, or regulatory risks noted in risk factors.
- No numeric full-year EPS bridge in the quarterly filing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q1 2026
+7.2%
Avg return
Earnings day
+12.4%
Avg return
5 days after
+871.4%
Avg return
30 days after
73%
8 / 11 earnings
Positive
+24.4%
Q4 2023
Best reaction
-16.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.7% | +15.9% | — | |
| Q4 2025 | +0.2% | -8.2% | -13.9% | |
| Q3 2025 | +15.4% | +26.8% | +33.1% | |
| Q2 2025 | +16.1% | +25.3% | +39.5% | |
| Q1 2025 | +17.3% | +24.3% | +8632.9% | |
| Q3 2024 | +7.0% | +7.0% | +27.1% | |
| Q2 2024 | +19.2% | +8.3% | -5.4% | |
| Q1 2024 | -7.0% | +25.5% | +13.1% | |
| Q4 2023 | +24.4% | +27.1% | +19.3% | |
| Q3 2023 | -16.0% | -9.4% | -21.5% | |
| Q2 2023 | -5.4% | -6.8% | -10.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro